Zoom: The important thing about MANF to focus on i
Post# of 30028
Posted On: 03/16/2015 9:35:20 AM
Zoom: The important thing about MANF to focus on in the next year is the "Eye Franchise:" Retinitis, Glaucoma, Macular Degeneration, etc. This is a huge market. It is our lead indication. Clinical trials will begin in Q4 2015. Maybe we will partner on it a year later. 4 years from now it might be commercialized and be a huge success for AMBS.
Diabetes/Wolframs would be even bigger, but it is not our lead indication and it isn't nearly as certain for us as is the Eye Franchise.
Diabetes/Wolframs would be even bigger, but it is not our lead indication and it isn't nearly as certain for us as is the Eye Franchise.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼